IP Library Patent Application 12576829
Patent Application
App. No. 12/576,829

METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/576,829
Abstract

A medicament safe and free from side effects, for the prevention or treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, which suppresses the progress of the condition and improves the quality of life of the patient, which medicament treats dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen by including a quiazoline derivative having the formula (I) or (II) or its pharmaceutically acceptable salt as an effective ingredient:

Claims (7)

1 - 16 . (canceled)

17 . A method for prevention or treatment of dermatitis exhibiting a biphasic skin reaction comprising administering to a patient in need of such treatment a chymase inhibitor in an amount effective for alleviating late-phase reaction.

18 . A method according to claim 17 , wherein the dermatitis exhibiting a biphasic skin reaction is atopic dermatitis.

19 . A method for alleviation of late-phase reaction of dermatitis exhibiting biphasic skin reaction comprising administering a chymase inhibitor to a patient in need of such treatment in an amount effective for alleviating late-phase reaction of dermatitis exhibiting biphasic skin reaction.

20 . A method according to claim 19 , wherein said dermatitis exhibiting a biphasic skin reaction is atopic dermatitis.

21 . A method for the prevention or treatment of dermatitis induced by repeated exposure to an antigen comprising administering a chymase inhibitor to a patient in need of such treatment in an amount effective for prevention or treatment of said dermatitis.

22 . A method according to claim 21 , wherein said dermatitis induced by repeated exposure to an antigen is atopic dermatitis.

Assignments (1)
MERGER Recorded Aug 18, 2010
From: ASUBIO PHARMA CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 024851/0521 →